Podcast Host Disclosures:

Dr. Black has received honoraria from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Biosyent, Bristol- Myers Squibb, EMD-Serono, Ferring, Janssen Oncology, Merck, Nanology, Nonagen, Pfizer, Prokarium, Protara, QED, Roche Canada, Sanofi Canada, STIMIT, Urogen Pharma and Verity

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits.

Obtain Section 3 Credits Here >

Podcast Host Disclosures:

Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura. Committees: NCCN, GU Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. 

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

Bladder Cancer Canada

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.